Animal Rule Information
Before a medical product can be approved by FDA, the sponsor must prove efficacy—that the product works. In some cases, such as developing medical countermeasures for potential bioterror threats, human challenge studies (exposing people to the threat agent) would not be ethical or feasible.
In these cases, FDA may grant approval based on well-controlled animal studies, when the results of those studies establish that the drug or biologic product is reasonably likely to produce clinical benefit in humans. The product sponsor must still demonstrate the product’s safety in humans.
Animal Rule Links
- Draft Guidance: Product Development Under the Animal Rule (PDF - 1.3MB)
- June 3, 2014 Federal Register notice: Product Development Under the Animal Rule; Revised Draft Guidance for Industry (comment by August 4, 2014)
- Webcast recording: Product Development Under the Animal Rule - Revised Draft Guidance for Industry (June 3, 2014)
Animal Rule Q&As Activities to Encourage Development, Qualification, and Use of Animal Models Animal Rule Summary
- 21 CFR 314.600 (drugs)
- 21 CFR 601.90 (biological products)
PAHPRA's Provisions Related to Development of MCMs Under the Animal Rule Animal Model Qualification Program
- Animal Model Qualification: Frequently Asked Questions
- Countering Bioterrorism Questions and Answers from CBER
- FDA Basics: Why are animals used for testing medical products?
Product Approval Announcements
FDA news announcements for products approved under the Animal Rule
- March 25, 2015: FDA approves treatment for inhalation anthrax (Anthrasil, Anthrax Immune Globulin Intravenous (Human))
- December 12, 2012: FDA approves raxibacumab to treat inhalational anthrax
- December 15, 2006: FDA Approves Drug to Treat Cyanide Poisoning (Cyanokit) [ARCHIVED]
- February 5, 2003: FDA approves pyridostigmine bromide as pretreatment against nerve gas